Effect of candesartan on New York Heart Association functional class - Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

European Heart Journal

Volumn 25, Issue 21, 2004, Pages 1920-1926

  O'Meara, Eileen ^a   Solomon, Scott ^b   McMurray, John ^a   Pfeffer, Marc ^b   Yusuf, Salim ^c   Michelson, Eric ^d   Granger, Chris ^e   Olofsson, Bertil ^f   Young, James B ^g   Swedberg, Karl ^h  

^a WESTERN INFIRMARY   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Ontario Canada   (Canada)

^d ASTRAZENECA   (United Kingdom)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f ASTRAZENECA R AND D   (Sweden)

^g LERNER RESEARCH INSTITUTE   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin receptor blockers; Heart failure; New York Heart Association (NYHA) functional class

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE CALCULATION; DRUG EFFECT; FEMALE; HEALTH PROGRAM; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME;

EID: 7544246246     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.07.025     Document Type: Article

References (22)

1. Criteria Committee NYHA. In: Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. Boston, MA: Little Brosn & Co Inc; 1964, p. 114
2. J.A. Bennett, B. Riegel, and V. Bittner Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease Heart Lung 31 2002 262 270
3. V. Brittner, D.H. Weiner, and S. Yusuf Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators JAMA 270 1993 1702 1707
4. L. Gorkin, N.K. Norvell, and R.C. Rosen Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy Am. J. Cardiol. 71 1993 1069 1073
5. C. Rostagno, G. Galanti, and M. Comeglio Comparison of different methods of functional evaluation in patients with chronic heart failure Eur. J. Heart Fail 2 2000 273 280
6. M.H. Drazner, J.E. Rame, and L.W. Stevenson Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure N. Engl. J. Med. 345 2001 574 581
7. C. Rostagno, G. Olivo, and M. Comeglio Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation Eur. J. Heart Fail. 5 2003 247 252
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435
9. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-544
10. E.J. Brown Jr., P.H. Chew, and A. MacLean Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group Am. J. Cardiol. 75 1995 596 600
11. T. Gundersen, K. Swedberg, and O. Amtorp Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group Eur. Heart J. 15 1994 1659 1665
12. L. Erhardt, A. MacLean, and J. Ilgenfritz Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group Eur. Heart J. 16 1995 1892 1899
13. [No authors listed]. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007
14. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N. Engl. J. Med. 341 1999 709 717
15. C.B. Granger, J.J. McMurray, and S. Yusuf CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
16. J.J. McMurray, J. Ostergren, and K. Swedberg CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
17. S. Yusuf, M.A. Pfeffer, and K. Swedberg CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
18. M.A. Pfeffer, K. Swedberg, and C.B. Granger CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
19. C.B. Granger, G. Ertl, and J. Kuch Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors Am. Heart J. 139 2000 609 617
20. J. McMurray, J. Östergren, and M. Pfeffer Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) pogramme Eur. J. Heart Fail. 5 2003 261 270
21. J.N. Cohn, and G. Tognoni Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 345 2001 1667 1675
22. G.A. Riegger, H. Bouzo, and P. Petr Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators Circulation 100 1999 2224 2230